HC Wainwright Has Negative Forecast for Ocugen Q1 Earnings

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Research analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for shares of Ocugen in a report released on Thursday, March 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.05) for the quarter, down from their prior estimate of ($0.04). HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Ocugen's current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen's Q2 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.25) EPS, FY2027 earnings at ($0.11) EPS and FY2028 earnings at $0.21 EPS.

Separately, Chardan Capital increased their target price on Ocugen from $6.00 to $7.00 and gave the company a "buy" rating in a research report on Thursday, March 6th.

Ocugen Price Performance

OCGN traded down $0.01 during trading on Monday, hitting $0.54. The company's stock had a trading volume of 2,734,681 shares, compared to its average volume of 5,616,115. The firm has a market capitalization of $156.90 million, a price-to-earnings ratio of -2.98 and a beta of 3.88. Ocugen has a twelve month low of $0.52 and a twelve month high of $2.11. The business's fifty day simple moving average is $0.70 and its 200 day simple moving average is $0.89. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04.

Remove Ads

Ocugen (NASDAQ:OCGN - Get Free Report) last posted its earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. During the same period in the previous year, the firm earned ($0.03) EPS.

Institutional Investors Weigh In On Ocugen

Several large investors have recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Ocugen by 7.1% in the third quarter. State Street Corp now owns 15,824,517 shares of the company's stock worth $15,701,000 after acquiring an additional 1,047,896 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Ocugen by 4.9% in the 4th quarter. Geode Capital Management LLC now owns 6,588,407 shares of the company's stock valued at $5,305,000 after purchasing an additional 309,853 shares in the last quarter. Northern Trust Corp boosted its stake in Ocugen by 10.4% during the 4th quarter. Northern Trust Corp now owns 2,407,137 shares of the company's stock worth $1,938,000 after purchasing an additional 227,150 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Ocugen during the fourth quarter worth $1,681,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Ocugen by 12.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 860,244 shares of the company's stock valued at $692,000 after buying an additional 93,288 shares during the last quarter. 10.27% of the stock is currently owned by hedge funds and other institutional investors.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.